The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/1000. Detects a band of approximately 100 kDa (predicted molecular weight: 76 kDa).
Involved in innate immunity against invading pathogens. Adapter used by TLR3 and TLR4 (through TICAM2) to mediate NF-kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis. Ligand binding to these receptors results in TRIF recruitment through its TIR domain. Distinct protein-interaction motifs allow recruitment of the effector proteins TBK1, TRAF6 and RIPK1, which in turn, lead to the activation of transcription factors IRF3 and IRF7, NF-kappa-B and FADD respectively.
Ubiquitously expressed but with higher levels in liver.
Contains 1 TIR domain.
The N-terminal region is essential for activation of the IFNB promoter activity.
Lane 1 : HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate Lane 2 : Ramos (Human Burkitt's lymphoma cell line) whole cell lysate Lane 3 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate Lane 4 : Human fetal lung lysate Lane 5 : Human fetal heart lysate Lane 6 : Human fetal kidney lysate
Lysates/proteins at 10 µg per lane.
Secondary Lanes 1 - 4 : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution Lanes 5 - 6 : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution
TRIF was immunoprecipitated from 0.35 mg of HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate with ab180689 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab180689 at 1/1000 dilution. VeriBlot for IP secondary antibody (HRP) (ab131366), was used as secondary antibody at 1/10000 dilution.
Lane 1: HepG2 whole cell lysate 10µg (Input).
Lane 2: ab180689 IP in HepG2 whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab180689 in HepG2 whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.